Gadolinium labeled pharmaceuticals as potential mri contrast agents for liver and biliary tract

✍ Scribed by A. Najafi; E. E. Amparo; R. R. Johnson Jr.

• Publisher: John Wiley and Sons
• Year: 1987
• Tongue: French
• Weight: 480 KB
• Volume: 24
• Category: Article
• ISSN: 0022-2135
• DOI: 10.1002/jlcr.2580240915

✦ Synopsis

Three gadolinium-labeled compounds, potential nuclear magnetic resonance (hTlR) imaging contrast agents for liver and biliary tract, were studied: I ) Gd-DISIDA, 2 ) Gd-DTPA-Liposomes, and 3 ) Gd-DTPA dihexadecylamide (Gd-diamide). In each case, "Carrier Added" Gd-153 with specific activity of about 5uCi/mg was used. Each labeled compound was evaluated in experimental animals. Gd-DISTDA proved unsatisfactory because of in vivcj instability. probably due to pulmonary embolism when large amounts of this compound was administered intravenously. Gd-diamide showed good uptake in the hepatocytes with subsequent excretion into the biliary tract. Several rabbits were imaged in a O.hT NMR imaging system before and after injection of Gd-di-anide. Pulse sequences were chosen that would yield T1-weighted images and permit calculation of 31 relaxation times.

This compound produced significant shortening of the T1 relaxation times of the liver and ohservable increase in intensity on the T1-weighted images. Gd-diamide shows promise a s potential PTNR contrast agent for liver and biliary tract imaging.